NanoX - Model TLC178 - Anticancer Drug Vinorelbine
From Pipeline - Oncology
TLC178 is our proprietary NanoX™ formulation of the anticancer drug vinorelbine, developed for the treatment of rhabdomyosarcoma (RMS), a rare form of soft tissue sarcoma that most frequently occurs in children.
Details
Vinorelbine is a vinca alkaloid chemotherapy agent commonly used off-label to treat RMS and other sarcomas. TLC178 is a formulation of vinorelbine loaded into liposomes, designed to reduce toxicity and improve efficacy with fewer administrations.
We are initially developing TLC178 for pediatric RMS. The increased specificity of TLC178 for tumor versus non tumor tissue through the use of our NanoX™ technology, which utilizes enhanced permeability and retention effects, will enable greater dose intensity, with attendant benefits in antitumor response without impairing the safety profile. TLC178 will have significantly lower myelosuppression, resulting in a lower rate of severe neutropenia.
In parallel with the pediatric RMS study, we plan to conduct a series of trials evaluating TLC178 in STS and indications for which vinorelbine has been approved, such as non-small cell lung carcinoma.
API
Vinorelbine
DDS Platform
Indication
Soft tissue sarcoma / rhabdomyosarcoma / non-small cell lung carcinoma
Development Status
Phase I/II
Advantages
- Improved selective delivery to tumor vs non-tumor tissue
- Higher drug concentration at tumor confers higher activity
- Less drug to non-tumor sites to reduce myelosuppression, enabling higher dose frequency
- Efficacy imrpovement in treatment response rate and duration of response
Customer reviews
No reviews were found for NanoX - Model TLC178 - Anticancer Drug Vinorelbine. Be the first to review!